Update on pathogenesis, markers and management of diabetic nephropathy

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 3, 1996, Pages 243-253

  Mogyorósi, András ^a   Ziyadeh, Fuad N ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; MICROALBUMINURIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; HUMANS; NEPHROLOGY;

EID: 0030009877     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199605000-00010     Document Type: Review

References (150)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462.
3. Ziyadeh FN, Goldfarb S: The diabetic renal tubulointerstitium. In Current topics in pathology Edited by Dodd S. Berlin: Springer-Verlag, 1995:175-201.
4. Kasinath BS, Block JA, Singh AK, Terhune WC, Maldonado R, Davalath S, Wanna L: Regulation of rat glomerular epithelial cell proteoglycans by high-medium glucose. Arch Biochem Biophys 1994, 309:149-159.
5. Takeuchi A, Throckmorton DC, Brogden AP, Yoshizawa N, Rasmussen H, Kashgarian M: Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 1995, 268:F13-F19.
6. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P: Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 1995, 96:1802-1814. This important paper provides direct evidence that increased glucose metabolism is the crucial parameter for increased matrix accumulation in mesangial cells. Cultured rat mesangial cells overexpressing the glucose transporter GLUT1 demonstrate markedly increased glucose uptake and metabolism as well as significant stimulation of matrix synthesis, even when the cells are grown in a normal extracellular glucose concentration.
7. Ziyadeh FN: Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabetic renal disease. Miner Electrolyte Metab 1995, 21:292-302. This report includes a review of cell culture studies examining the metabolic effects of high ambient glucose.
8. Adler S: Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 1994, 5:1165-1172.
9. McLennan SV, Fisher EJ, Yue DK, Turtle JR: High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 1994, 43:1041-1045.
10. Leehey DJ, Hua Song R, Alavi N, Singh AK: Decreased degradative enzymes in mesangial cells cultured in high glucose media. Diabetes 1995, 44:929-935.
11. Yagame M, Kim YK, Zhu D, Suzuki D, Eguchi K, Nomoto Y, Sakai H, Groppoli T, Steffes MW, Mauer SM: Differential distribution of type IV collagen chains in patients with diabetic nephropathy in noninsulin-dependent diabetes mellitus. Nephron 1995, 70:42-48.
12. van den Born J, van Kraats AA, Bakker MAH, Assmann KJM, van den Heuvel LPWJ, Veerkamp JH, Berden JHM: Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 1995, 38:161-172.
13. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994, 266:F829-F842.
14. Border WA, Noble NA: Transforming growth factor-beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
15. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44:1139-1146. A detailed review of the evidence derived from cell culture and experimental animals linking the autocrine overproduction of TGF-β and diabetic renal disease.
16. Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994, 93:536-542. The high glucose-mediated increase in collagen synthesis in mesangial cells is blocked by a neutralizing anti-TGF-β antibody. This paper provides the first evidence that the short-term effects of high ambient glucose on matrix synthesis are mediated by increased production and activity of autocrine TGF-β.
17. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor-beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993, 90:1814-1818.
18. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993, 42:450-456.
19. Sharma K, Ziyadeh FN: Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994, 267:F1094-F1101.
20. Pankewycz OG, Guan JX, Bolton WK, Gomez A, Benedict JF: Renal TGF-beta regulation in spontaneously diabetic NOD mice with correlations in mesangial cells. Kidney Int 1994, 46:748-758.
21. Shankland SJ, Scholey JW: Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int 1994, 46:430-442.
22. Yang CW, Hattori M, Vlassara H, He CJ, Carome MA, Yamato E, Elliot S, Striker GE, Striker U: Overexpression of transforming growth factor-beta 1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol 1995, 5:1610-1617.
23. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and enhanced extracellular matrix gene expression in streptozotocin-diabetic mice. Diabetes 1996, 45:522-530.
24. DeRubertis FR, Craven PA: Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994, 43:1-8.
25. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hyperglycemia. Diabetes 1994, 43:1122-1129.
26. Fumo P, Kuncio GS, Ziyadeh FN: PKC and high glucose stimulate collagen alpha1(IV) transcriptional activity in a reporter mesangial cell line. Am J Physiol 1994, 267:F632-F638.
27. Kreisberg JI, Radnik RA, Ayo SH, Garoni JA, Saikumar P: High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures. Kidney Int 1994, 46:105-112.
28. Shankland SJ, Scholey JW: Expression of growth-related protooncogenes during diabetic renal hypertrophy. Kidney Int 1995, 47:782-788.
29. Kreisberg JI, Kreisberg SH: High glucose activates protein kinase C and stimulates fibronectin gene expression by enhancing a cAMP response element. Kidney Int 1995, (suppl 51):S3-S11.
30. Kikkawa R, Haneda M, Uzu T, Togawa M, Koya D, Kajiwara N, Shigeta Y: Translocation of protein kinase Cα and ζ in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia 1994, 37:838-841.
31. Sharma K, Danoff TM, DePiero A, Ziyadeh FN: Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. Biochem Biophys Res Comm 1995, 207:80-88.
32. Geiser AG, Kim SJ, Roberts AB, Sporn MB: Characterization of the mouse transforming growth factor-β1 promoter and activation by the Ha-ras oncogene. Mol Cell Biol 1991, 11:84-92.
33. Studer RK, Negrete H, Craven PA, DeRubertis FR: Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-beta bioactivity in mesangial cells. Kidney Int 1995, 48:422-430.
34. Negrete H, Studer RK, Craven PA, DeRubertis FR: Role for transforming growth factor-beta in thromboxane-induced increases in mesangial cell fibronectin synthesis. Diabetes 1995, 44:335-339.
35. 2+ mobilization. Biochem Biophys Res Comm 1995, 210:378-383.
36. Jaffa AA, Rust PF, Mayfield RK: Kinin: a mediator of diabetes induced hyperfiltration. Diabetes 1995, 44:156-160.
37. Cheng HF, Burns KD, Harris RC: Reduced proximal tubule angiotensin II receptor expression in streptozotocin induced diabetes mellitus. Kidney Int 1995, 46:1603-1610.
38. Wolf G, Mueller E, Stahl RAK, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous TGF-β. J Clin Invest 1993, 92:1368-1373.
39. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-2437.
40. Abrass CK, Spicer D, Raugi GJ: Induction of nodular sclerosis by insulin in rat mesangial cells in vitro: Studies of collagen. Kidney Int 1995, 47:25-37.
41. 2+ independent Diabetes 1995, 44:759-766.
42. Ling BN, Seal EE, Eaton DC: Regulation of mesangial cell ion channels by insulin and angiotensin II - possible role in diabetic glomerular hyperfiltration. J Clin Invest 1993, 92:2141-2151.
43. Traub O, Van Bibber R: Role of nitric oxide in insulin-dependent diabetes mellitus-related vascular complications. West J Med 1995, 162:439-445.
44. Pfeilschifter J: Does nitric oxide, an inflammatory mediator of glomerular mesangial cells, have a role in diabetic nephropathy? Kidney Int 1995, (suppl 51):S50-S60.
45. Arima S, Ito S, Omata K, Takeuchi K, Abe K: High glucose augments angiotensin II action by inhibiting NO synthesis in in-vitro microperfused rabbit afferent arterioles. Kidney Int 1995, 48:683-689.
46. Takahashi K, Ghatei MA, Lam H-C, O'Halloran DJ, Bloom SR: Elevated plasma endothelin levels in patients with diabetes mellitus. Diabetologia 1990, 33:306-310.
47. Ferri C, Laurenti O, Bellini C, Faldetta MRC, Properzi G, Santucci A, De Mattia G: Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patients. Am J Hypertens 1995, 8:40-47.
48. Dohi Y, Hahn AW, Boulanger CM, Buhler FR, Luscher TF: Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992, 19:131-137.
49. Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R: Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 1995, 18:87-89.
50. Morabito E, Corsico N, Arrigoni Martelli E: Endothelins urinary excretion in spontaneously diabetic rats: BB/BB. Life Sciences 1995, 56:13-18.
51. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H: Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995, 44:895-899. This paper provides provocative evidence for increased glomerular endothelins in the pathogenesis of matrix expansion in diabetic rats.
52. Fukui M, Nakamura T, Ebihara I, Makita Y, Osada S, Tomino Y, Koide H: Effects of enalapril on endothelin-1 and growth factor expression in diabetic rat glomeruli. J Lab Clin Med 1994, 123:763-768.
53. Boel E, Selmer J, Flodgaard HJ, Jensen T: Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise? J Diabetes Compl 1995, 9:104-129.
54. Goldfarb S, Ziyadeh FN, Kern EFO, Simmons DA: Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes 1991, 40:465-471.
55. Pedersen MM, Christiansen JS, Mogensen CE: Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 months of aldose reductase inhibition. Diabetes 1991, 40:527-531.
56. Bleyer AJ, Fumo P, Snipes ER, Goldfarb S, Simmons DA, Ziyadeh FN: Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule. Kidney Int 1994, 45:659-666.
57. Clark CM, Lee DA: Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995, 332:1210-1217. An excellent, in-depth review of the management of neuropathy, retinopathy and nephropathy.
58. Yamaoka T, Nishimura C, Yamshita K, Itakura M, Yamada T, Fujimoto J, Kokai Y: Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 1995, 38:255-261.
59. Williamson JR, Chang K, Frangos M, Hasan K, Ido Y, Kawamura T, Nyengaard JR, Van Den Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993, 42:801-813.
60. Cohen AM, Wald H, Popovtzer M, Rosenmann E: Effect of myoinositol supplementation on the development of renal pathological changes in the Cohen diabetic (type 2) rat. Diabetologia 1995, 38:899-905.
61. Abe T, Takeuchi K, Takahashi N, Tsutsumi E, Taniyama Y, Abe K: Rat kidney thromboxane receptor: molecular cloning, signal transduction, and intrarenal expression localization. J Clin Invest 1995, 96:657-664.
62. Kontessis PS, Jones SL, Barrow SE, Stratton PD, Alessandrini P, De Cosmo S, Ritter JM, Viberti GC: Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. J Lab Clin Med 1993, 121:415-423.
63. Matsuo Y, Takagawa I, Koshida H, Kawabata T, Nakamura M, Ida T, Zhou L, Marumo F: Antiproteinuric effect of a thromboxane receptor antagonist S-1452, on rat diabetic nephropathy and murine lupus nephritis. Pharmacology 1995, 50:1-8.
64. Williams B, Schrier RW: Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J Clin Invest 1993, 92:2889-2896.
65. Mahadevan P, Larkins RG, Fraser JRE, Fosang AJ, Dunlop ME: Increased hyaluronan production in the glomeruli from diabetic rats: a link between glucose-induced prostaglandin production and reduced sulphated proteoglycan. Diabetologia 1995, 38:298-305.
66. Brownlee M: Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1995, 46:223-234.
67. Cohen MP, Ziyadeh FN: Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol 1996, 7:183-190. The only available review on the biology of Amadori-modified proteins and their link to the pathogenesis of diabetic nephropathy.
68. Bucala R, Vlassara H: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995, 26:875-888. A comprehensive updated review of the in-vitro and in-vivo evidence linking advanced glycosylation to diabetic kidney disease.
69. Cohen MP, Ziyadeh FN: Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int 1994, 45:475-484.
70. Cohen MP, Hud E, Wu VY, Ziyadeh FN: Glycated albumin modified by Amadori adducts modulates aortic endothelial cell biology. Mol Cell Biochem 1995, 143:73-79.
71. Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, Ziyadeh FN: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. J Clin Invest 1995, 95:2338-2345. The first in-vivo study establishing a pathogenetic effect of Amadori-glycated albumin in diabetic nephropathy. Neutralizing the effects of the elevated circulating glycated albumin concentration in diabetic db/db mice by monoclonal antibodies (A717) specific for Amadori-glycated albumin is associated with a reduction in proteinuria and mesangial matrix expansion, and prevention of the overexpression of mRNAs encoding type IV collagen and fibronectin in the renal cortex.
72. Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, Ota Z, Araki N, Horiuchi S: Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995, 48:517-526.
73. Nishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, Dohi K: Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Hum Pathol 1995, 26:308-313.
74. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H: Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995, 44:824-829.
75. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M: PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995, 48:111-117.
76. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern O: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 1995, 96:1395-1403. A functional role of a putative receptor for AGE (RAGE) is suggested as the basis for the observed biological effect of AGE-modified proteins on endothelial cells.
77. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker U: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994, 91:9436-9440.
78. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat Diabetologia 1995, 38:367-394.
79. Trachtman H, Futterweit S, Prenner J, Hanon S: Antioxidants reverse the antiproliferative effect of high glucose and advanced glycosylation end products in cultured rat mesangial cells. Biochem Biophys Res Comm 1994, 199:346-352.
80. van Dam PS, van Asbeck BS, Erkelens DW, Marx JJM, Gispen WH, Bravenboer B: The role of oxidative stress in neuropathy and other diabetic complications. Diabet Metab Rev 1995, 11:181-192.
81. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, Kondo T: Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia 1995, 38:201-210.
82. Ha H, Yoon SJ, Kim KH: High glucose can induce lipid peroxidation in the isolated rat glomeruli. Kidney Int 1994, 46:1620-1626.
83. Trachtman H, Futterweit S, Maesaka J, Ma C, Valderrama E, Fuchs A, Tarectecan AA, Rao PS, Sturman JA, Boles TH et al.: Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats. Am J Physiol 1995, 269:F429-F438. A 1-year study showing the beneficial effect of dietary taurine supplementation and the deleterious effect of vitamin E in experimental diabetic nephropathy.
84. Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, Endoh M, Nomoto Y, Sakai H: In-situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 1995, 44:1233-1238.
85. Serri O, Beauregard H, Brazeau P, Abribat T, Lambert J, Harris A, Vachon L: Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 1991, 265:888-892.
86. Zador IZ, Deshmukh GD, Kunkel R, Johnson K, Radin NS, Shayman JA: A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J Clin Invest 1993, 91:797-803.
87. Pedersen SB, Bjorn SF, Richelsen B, Flyvbjerg A: Inhibition of renal ornithine decarboxylase activity fails to reduce kidney size and urinary albumin excretion in diabetic rats with manifest kidney hypertrophy. Mol Cell Endocrinol 1995, 107:123-128.
88. Leese GP, Vora JP: Clinical interventions in diabetic renal disease. Curr Opin Nephrol Hypertens 1995, 4:139-145.
89. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, Steffes MW, Striker GE: Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995, 25:107-112. Useful clinical guidelines for the diagnosis and therapy of microalbuminuria in diabetic patients.
90. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T: The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabetic Med 1995, 12:482-487.
91. Savage S, Johnson Nagel N, Estacio RO, Lukken N, Schrier RW: Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis 1995, 25:836-844. Predictors of microalbuminuria in a large study of NIDDM patients included: systolic hypertension, increased body mass index, decreased high-density lipoprotein cholesterol, insulin use and cigarette smoking.
92. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E, and the WHO Multinational Study Group: Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetic Med 1995, 12:149-155.
93. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995, 44:1303-1309. A significant correlation was found between microalbuminuria and overall mortality especially caused by cardiovascular complications.
94. Fioretto P, Steffes MW, Mauer M: Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994, 43:1358-1364. An important study of sequential kidney biopsy demonstrating that IDDM patients with increasing mesangial matrix expansion have progression of microalbuminuria.
95. Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI: Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994, 43:1046-1051.
96. Wirta O, Pasternack A, Mustonen J, Oksa H, Koivula T, Helin H: Albumin excretion rate and its relation to kidney disease in noninsulin-dependent diabetes mellitus. J Intern Med 1995, 237:367-373.
97. Trevisan R, Viberti GC: Genetic factors in the development of diabetic nephropathy. J Lab Clin Med 1995, 126:342-349. A thorough review of genetic susceptibility with special emphasis on membrane transporters and polymorphism of the genes of the components of the renin-angiotensin system.
98. Angelico MC, Laffer LMB, Krolewski AS: Application of denaturing gradient gel electrophoresis to detect DNA polymorphisms in the renin gene in IDDM patients with or without nephropathy. In Current topics in diabetic research. Edited by Belfiore F, Bergman RN, Molinatti GM. Basel: Karger; 1993, 12:227-230.
99. Fogarty DG, Hughes AE, Nevin NC, Doherty CC, Maxwell AP: Functional genetic markers of the renin-angiotensin system and risk of diabetic nephropathy in insulin-dependent diabetes mellitus. J Am Soc Nephrol Abstr 1994, 5:376A.
100. Tarnow L, Cambien F, Rossing P, Nielsin FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving HH: Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995, 44:489-494.
101. Schmidt S, Schone N, Ritz E, and the Diabetic Nephropathy Study Group: Association of ACE gene polymorphism and diabetic nephropathy? Kidney Int 1995, 47:1176-1181. ACE gene insertion/deletion polymorphism was not associated with suceptibility to diabetic nephropathy in a large European population of IDDM and NIDDM patients.
102. Powrie JK, Watts GF, Ingham JN, Taub NA, Talmud PJ, Shaw KM: Role of glycaemic control in the development of microalbuminuria in patients with insulin dependent diabetes. BMJ 1994, 309:1608-1612.
103. Fujisawa T, Ikegami H, Shen GQ, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Ueda H, Rakugi H, Higaki J, et al.: Angiotensin I-converting enzyme polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care 1995, 18:983-985.
104. Dudley CRK, Keavney B, Stratton IM, Turner RC, Ratcliffe PJ: U.K. Prospective Diabetes Study XV: relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM. Kidney Int 1995, 48:1907-1911. Whereas ACE gene insertion/deletion polymorphism was not associated with a susceptibility for diabetic nephropathy in NIDDM patients, such polymorphism predicted the progression of established diabetic nephropathy defined by baseline microalbuminuria.
105. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Boelskifte S, Borch-Johnsen K, Parving HH: Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 1990, 38:798-803.
106. + exchanger isoform-1 abundance in skin fibroblasts of type I diabetic patients with nephropathy. Metabolism 1995, 44:791-795.
107. + exchanger of immortalized lymphoblasts from type I diabetic patients with nephropathy. Diabetes 1995, 44:382-388.
108. + exchanger isoform 1 of immortalized lymphoblasts in diabetic nephropathy. Diabetes 1995, 44:1180-1185.
109. Houtman PN, Campbell FM, Shah V, Grant DB, Dunger DB, Dillon MJ: Sodium-lithium countertransport in children with diabetes and their families. Arch Dis Child 1995, 72:133-136.
110. Fujita J, Tsuda K, Seno M, Obayashi H, Fukui I, Seino Y: Erythrocyte sodium-lithium countertransport activity as a marker of predisposition to hypertension and diabetic nephropathy in NIDDM. Diabetes Care 1994, 17:977-982.
111. Pinkney JH, Foyle WJ, Denver AE, Mohamed-Ali V, McKinlay S, Yudkin JS: The relationship of urinary albumin excretion rate to ambulatory blood pressure and erythrocyte sodium-lithium countertransport in NIDDM. Diabetologia 1995, 38:356-362.
112. Brenner BM, Cherfow GM: Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 1994, 23:171-175.
113. Rossing P, Tarnow L, Nielsen FS, Boelskifte S, Brenner BM, Parving HH: Short stature and diabetic nephropathy. BMJ 1995, 310:296-297.
114. Nielsen FS, Gall MA, Parving HH: Acquired oligonephropathy and diabetic nephropathy. Am J Kidney Dis 1995, 26:898-903.
115. Pickup JC, Mattock MB, Crook MA, Chusney GD, Burt D, Fitzgerald AP: Serum sialic acid concentration and coronary heart disease in NIDDM. Diabetes Care 1995, 18:1100-1103.
116. Crook MA, Earle K, Morocutti A, Yip A, Viberti GC, Pickup JC: Serum sialic acid, a risk factor for cardiovascular disease, is elevated in IDDM patients with microalbuminuria and clinical proteinuria. Diabetes Care 1994, 17:305-310.
117. Yokoyama H, Jensen JS, Jensen T, Deckert T: Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy. J Intern Med 1995, 237:519-523.
118. Waters PJ, Flynn MD, Pennock CA, Corrall RJM, Greenwood RJ, Eisenthal R: Decreased sialidase activity in mononuclear leucocytes of type 1 diabetic subjects: relationship to diabetic complications and glycaemic control. Diabetic Med 1995, 12:670-673.
119. Ozata M, Kurt I, Azal O, Bolu E, Corakci A, Beyhan Z, Karaca L, Gundogan MA: Can we use plasma fibronectin levels as a marker for early diabetic nephropathy? Endocrine J 1995, 42:301-305.
120. Okazaki R, Matsuoka K, Atsumi Y, Maruyama K, Matsuki H, Okazaki I: Serum concentrations of basement membrane proteins in NIDDM as a prognostic marker for nephropathy. Diabetes Res Clin Pract 1995, 27:39-49.
121. Rudberg S, Persson B: Association between lipoprotein(a) and insulin-like growth factor I during puberty and the relationship to microalbuminuria in children and adolescents with IDDM. Diabetes Care 1995, 18:933-939.
122. Groop PH, Viberti GC, Elliott TG, Friedman R, Mackie A, Ehnholm C, Jauhiainen M, Taskinen MR: Lipoprotein(a) in type 1 diabetic patients with renal disease. Diabetic Med 1994, 11:961-967.
123. Reichard P, Nilsson B, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993, 329:304-309.
124. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trail. Kidney Int 1995, 47:1703-1720. This subgroup analysis of the DCCT study discusses the beneficial effects of intensive therapy on the development and progression of diabetic nephropathy in IDDM patients. Intensive therapy in patients with initial normoalbuminuria was associated with a decreased incidence of microalbuminuria. However, if microalbuminuria was present at entry into the study, intensive insulin therapy did not provide a statistically different effect compared with conventional therapy on the subsequent progression to macroalbuminuria.
125. Viberti GC, on behalf oi the Microalbuminuria Collaborative Study Group: Intensive therapy fails to prevent overt nephropathy in insulin-dependent diabetics with microalbuminuria [Abstract]. Diabetologia 1994, 37(suppl 1):A196.
126. Krolewski AS, Laffel LMB, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995, 332:1251-1255. A retrospective analysis demonstrating that the risk of microalbuminuria increases abruptly above a glycosylated hemoglobin level of 8.1% in IDDM patients with initial normoalbuminuria.
127. Reichard P: Are there any glycemic thresholds for the serious microvascular diabetic complications? J Diabetes Compl 1995, 9:25-30.
128. Poulsen PL, Hansen KW, Mogensen CE: Ambulatory blood pressure in the transition from normo- to microalbuminuria. Diabetes 1994, 43:1248-1253.
129. Nielsen FS, Rossing P, Bang LE, Svendsen TL, Gall MA, Smidt UM, Parving HH: On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. Diabetes 1995, 44:783-789.
130. Mulec H, Blohme G, Kullenberg K, Nyberg G, Bjorck S: Latent overhydration and nocturnal hypertension in diabetic nephropathy. Diabetologia 1995, 38:216-220.
131. Schmitz A, Vaeth M, Mogensen CE: Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 1994, 37:1251-1258.
132. Parving HH, Rossing P, Hommel E, Smidt UM: Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995, 26:99-107.
133. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995, 47:907-910.
134. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990, 38:384-394.
135. Ong ACM, Fine LG: Loss of glomerular function and tubulointerstitial fibrosis. Cause or effect? Kidney Int 1994, 45:345-351.
136. Mogensen CE: Diabetic renal disease: the quest for normotension - and beyond. Diabetic Med 1995, 12:756-769. A thought-provoking historical overview of the putative risks of antihypertensive therapy and the recent recognition of its overriding benefits in diabetic nephropathy.
137. Ravid M, Savin H, Jutrin I, Bental T, Lang R: Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int 1994, (suppl 45):S161-S164.
138. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, Rohde RD, Lewis EJ, and the Collaborative Study Group: Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994, 46:1688-1693.
139. Sassy-Prigent C, Heudes D, Jouquey S, Auberval D, Belair MF, Michel O, Hamon G, Bariety J, Brunevl P: Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats - Protective effects of ACE inhibition. Lab Invest 1995, 73:64-71.
140. Walker JD, Dodds RA, Murrells TJ, Bending JJ, Mattock MB, Keen H, Viberti GC: Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989, ii:1411-1415.
141. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR: Effect of restricting dietary protein on the progression of renal failure in patients with diabetes mellitus. N Engl J Med 1991, 324:78-84.
142. Manto A, Cotroneo P, Marra G, Magnani P, Tilli P, Greco AV, Ghirlanda G: Effect of intensive treatment on diabetic nephropathy in patients with type I diabetes. Kidney Int 1995, 47:231-235.
143. American Diabetes Association, National Kidney Foundation: Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994, 17:1357-1361.
144. Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, Border WA: Dietary protein restriction rapidly reduces transforming growth factor-β1 expression in experimental glomerulonephritis. Proc Natl Acad Sci U S A 1991, 88:9765-9769.
145. Eddy AA: Protein restriction reduces transforming growth factor-beta and interstitial fibrosis in nephrotic syndrome. Am J Physiol 1994, 266:F884-F893.
146. Velasquez MT, Abraham AA, Kimmel PL, Farkas-Szallasi T, Michaelis OE: Diabetic glomerulopathy in the SHR/N-corpulent rat: role of dietary carbohydrate in a model of NIDDM. Diabetologia 1995, 38:31-38.
147. Williams ME: Management of the diabetic transplant recipient Kidney Int 1995, 48:1660-1674. A concise, up-to-date 'Nephrology Forum' discussing the outcome and management of renal transplantation in diabetic patients.
148. Barbosa J, Steffes MW, Sutherland DE, Connett JE, Rao KV, Mauer SM: Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. JAMA 1994, 272:600-606.
149. Wilczek HE, Jaremko G, Tyden G, Groth CG: Evolution of diabetic nephropathy in kidney grafts. Evidence that a simultaneously transplanted pancreas exerts a protective effect. Transplantation 1995, 59:51-57.
150. Wenzel UO, Fouqueray B, Biswas P, Grandaliano G, Choudhury GG, Abboud HE: Activation of mesangial cells by the phosphatase inhibitor vanadate. Potential implications for diabetic nephropathy. J Clin Invest 1995, 95:1244-1252.